List of Excipients in Branded Drug ZANAFLEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT RX USA LLC	ZANAFLEX	tizanidine hydrochloride	16590-871	GELATIN
STAT RX USA LLC	ZANAFLEX	tizanidine hydrochloride	16590-871	HYDROXYMETHYL CELLULOSE
STAT RX USA LLC	ZANAFLEX	tizanidine hydrochloride	16590-871	SILICON DIOXIDE
STAT RX USA LLC	ZANAFLEX	tizanidine hydrochloride	16590-871	TITANIUM DIOXIDE
Rebel Distributors Corp	ZANAFLEX	tizanidine hydrochloride	21695-373	GELATIN

Generic Drugs Containing ZANAFLEX

Company	Ingredient	NDC	Excipient
Trifluent Pharma LLC	tizanidine hydrochloride	73352-090	CELLULOSE, MICROCRYSTALLINE
Trifluent Pharma LLC	tizanidine hydrochloride	73352-090	CROSCARMELLOSE SODIUM
Trifluent Pharma LLC	tizanidine hydrochloride	73352-090	FD&C BLUE NO. 1
Trifluent Pharma LLC	tizanidine hydrochloride	73352-090	FD&C RED NO. 40
Trifluent Pharma LLC	tizanidine hydrochloride	73352-090	GELATIN

What are the Most Frequently-Used Excipients in ZANAFLEX?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	FD&C BLUE NO. 1
1	FD&C RED NO. 40
1	GELATIN

Excipient Strategy and Commercial Opportunities for ZANAFLEX

Last updated: February 27, 2026

What are the current excipient components in ZANAFLEX formulations?

ZANAFLEX (tizanidine hydrochloride) formulations primarily include the active pharmaceutical ingredient (API) at 2 mg or 4 mg doses. The excipient profile generally comprises:

• Microcrystalline cellulose (filler)
• Lactose monohydrate (filler)
• Croscarmellose sodium (disintegrant)
• Magnesium stearate (lubricant)
• Starch (binder)

Exact excipient specifications can vary based on the manufacturer, but these are standard for immediate-release tablets.

How do excipient choices impact formulation stability and bioavailability?

Excipients influence drug stability, dissolution rate, absorption, and patient tolerability:

• Microcrystalline cellulose provides structural integrity.
• Lactose monohydrate acts as a filler and affects tablet weight.
• Croscarmellose sodium enhances disintegration, critical for absorption.
• Magnesium stearate reduces friction during tablet compression but can impact dissolution if used excessively.
• Starch binds ingredients and controls release profiles.

Choice of excipients must balance stability, manufacturability, and bioavailability to meet regulatory standards.

Can reformulation optimize ZANAFLEX’s properties?

Reformulation opportunities involve:

• Replacing lactose with non-dairy fillers for lactose intolerance.
• Utilizing superdisintegrants like crospovidone to improve disintegration.
• Incorporating modified-release matrices to extend duration and reduce dosing frequency.
• Reducing excipient load to minimize excipient-related adverse reactions.

Innovations focus on enhancing onset, duration of action, and tolerability, especially in formulations targeting specific patient populations.

What are key regulatory considerations regarding excipients?

Regulatory bodies such as the FDA and EMA require:

• Detailed excipient characterization, including sources and purity.
• Compatibility studies demonstrating excipient-API stability.
• Post-marketing surveillance to monitor adverse reactions related to excipients.
• Documentation of excipient disclosure in labeling for patient safety, especially for excipients like lactose, gluten, or dyes that may trigger allergies.

Any reformulation involves compliance with these standards and may require additional stability and bioequivalence studies.

What are commercial opportunities linked to excipient innovations?

Innovative excipient strategies can unlock several avenues:

• Market differentiation: Formulating lactose-free versions addresses lactose intolerance, expanding user base.
• Extended-release formulations: Using specific excipients to modify release profiles can command premium pricing.
• Patent extension: Reformulation with novel excipients may enable new patent filings, delaying generic entry.
• Regulatory exclusivity: New formulations not only improve therapeutics but can qualify for exclusivity periods.
• Cost reduction: Employing cost-effective, scalable excipients improves profit margins.

Companies can leverage these opportunities to improve brand positioning and expand market share.

What are potential challenges in excipient strategy for ZANAFLEX?

Challenges include:

• Ensuring bioequivalence with existing formulations, requiring comprehensive testing.
• Navigating regulatory pathways for reformulated products.
• Managing supply chain risks for specialized or proprietary excipients.
• Balancing cost versus performance when selecting excipients.
• Addressing patient-specific requirements, such as allergies or sensitivities.

Meticulous planning and validation are necessary to translate excipient innovations into successful product launches.

Key Takeaways

• Excipient selection affects drug stability, bioavailability, and tolerability for ZANAFLEX.
• Reformulation with alternative or novel excipients offers opportunities to improve efficacy and patient compliance.
• Regulatory adherence is essential, especially when introducing new excipients or formulations.
• Innovation in excipient strategies can enable market differentiation, patent protection, and cost management.
• Challenges include maintaining bioequivalence, regulatory approval, and supply chain reliability.

FAQs

1. Can excipient reformulation extend ZANAFLEX's dosing interval?
Yes. Incorporating modified-release excipients can prolong drug action, allowing less frequent dosing.

2. Are there non-lactose excipients suitable for ZANAFLEX to prevent intolerance issues?
Yes. Mannitol or hypromellose can replace lactose as fillers or binders.

3. What excipients can improve ZANAFLEX’s stability?
Antioxidants like ascorbic acid or suitable desiccants can enhance shelf-life when compatible with the API.

4. How can excipient choice affect patent prospects?
Novel excipients or unique formulations can support new patent filings, creating market exclusivity.

5. What regulatory hurdles exist for formulating extended-release ZANAFLEX?
Extended-release formulations require detailed bioequivalence and safety data, prolonging approval timelines.

---

References

[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Excipients in Drug Products.
[2] European Medicines Agency. (2019). Guideline on formulation of modified-release oral dosage forms.